Search
Methacetin methoxy-C-13
go.drugbank.com/drugs/DB15885InvestigationalSynonyms: p-Acetanisidine C-13Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigationalLumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calc...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBicyclol
go.drugbank.com/drugs/DB16014InvestigationalBicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEnsifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesLonapegsomatropin
go.drugbank.com/drugs/DB16220ApprovedInvestigationalLonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone (somatropin) indicated for the treatment of children 1 year and older, weighing at least 11.5 kg, with growth failure due to ...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalRelapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. Prognosis is poor and more effective therapies are needed to t...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesMiricorilant
go.drugbank.com/drugs/DB16234InvestigationalMiricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with ...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersTL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. TL-895 is under investigation in several clinical trials for its safety and ef...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates